1 AARTIDRUGS share price target reports by brokerages below. See what is analyst's view on AARTIDRUGS share price forecast, rating, estimates, valuation and prediction behind the target. You may use these research report forecasts for long-term to medium term for your investment or trades in 2020.
We recently met the management of Aarti Drugs to discuss its expansion plans, past obstacles and the path forward. With added capacities in a few of its therapies, we expect its revenue/PAT to clock 14.5%/32% CAGRs over FY19-21. We maintain our Buy rating, with an unchanged target of Rs 796.
We maintain our Buy rating on Aarti Drugs (ADL) and retain the TP to Rs910 based on 16x March’20 EPS of Rs56.8. ADL is the market leader in 9 out of 10 APIs manufactured by the company. That said, the company is likely to benefit from vertical integration which is likely to drive future growth. We expect margins to improve post the launch of new products and additional capacities of Ciprofloxacin and Metformin APIs in place. Key risks to our assumptions include slowdown in the domestic pharma market and regulatory risks for its manufacturing facilities.
SOURCE: Data from D'Market via Quandl. Intraday data delayed 15 minutes.
DISCLAIMER: Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and FrontPage will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein.